Positive step for US reimbursement of Nevisense
STOCKHOLM, SWEDEN, — November 2, 2020 — SciBase Holding AB ("SciBase") [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders, announced today that they have been granted a Category III CPT[®](CPT III) code from the American Medical Association (AMA) for their Nevisense melanoma detection test.SciBase is therefore very pleased to announce that their CPT III code application for the Nevisense melanoma detection test was approved at the AMA’s October meeting without opposition, according to the CPT Editorial Summary of Panel